Phaseline

Companies › Enlivex Therapeutics

Enlivex Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 2; Immunology; next expected readout Feb 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Allocetra
Allogeneic peripheral blood mononuclear cells in apoptotic stable state
–Phase 2Primary Knee Osteoarthritis; Temporomandibular Joint OsteoarthritisFeb 2027
Allocetra-OTS
cell-based therapy consisting of non-HLA-matched allogeneic peripheral blood mononuclear c
–Phase 1Osteoarthritis, Knee–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06748651AllocetraPhase 1Temporomandibular Joint OsteoarthritisImmunologyFeb 2026
NCT06233474Allocetra-OTSPhase 1Osteoarthritis, KneeImmunologyMar 2026
NCT07580716AllocetraPhase 2Primary Knee OsteoarthritisImmunologyFeb 2027

From the company's SEC filings

Cash of $2m on 2025-12-31; operating cash outflow about $10m a year; runway about 2 months at that burn, to Mar 2026; 0 of 1 coming phase 2-3 readouts fall inside that runway

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Quoin Pharmaceuticals Prime Gene Therapeutics Citryll Toll Biotech Co. Ltd. (Beijing) Ventus Therapeutics U.S.

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.